Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort [0.03%]
针对IDH1突变的急性髓系白血病患者的ivosidenib治疗：二期关键队列的最终五年结果报告
Jorge Cortes,Antonio Curti,Pierre Fenaux et al.
Jorge Cortes et al.
Background: Olutasidenib is an oral, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), FDA-approved for relapsed/refractory (R/R) acute myeloid leukemia (AML) based on a registrational, phase 2, open-label...
B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study [0.03%]
靶向B细胞成熟抗原的正电子发射型计算机断层显像/计算机断层成像技术在多发性骨髓瘤中的应用：一项首个人体研究
Tingfei Gu,Zhao Chen,Tianyao Wang et al.
Tingfei Gu et al.
B-cell maturation antigen (BCMA)-targeted positron emission tomography/computed tomography (PET/CT) represents a promising tool for the management of multiple myeloma, enabling noninvasive and quantitative evaluation across different diseas...
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape [0.03%]
靶向B7-H3的纳米抗体嵌合抗原受体T细胞控制多发性骨髓瘤生长，而双特异性BCMA/B7-H3 CAR-T细胞克服了抗原逃逸现象
Arne Van der Vreken,Fien Meeus,Chenggong Tu et al.
Arne Van der Vreken et al.
Background: CAR T cell therapy targeting BCMA has shown remarkable efficacy in multiple myeloma (MM), but relapses occur due to T cell exhaustion and the emergence of BCMA-negative subpopulations. Novel targets are needed...
Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma [0.03%]
BCL11B耗竭诱导的NK细胞定向重编程增强针对胰腺导管腺癌的免疫疗法
Han-Seop Kim,Jae Yun Kim,Ji-Young Lee et al.
Han-Seop Kim et al.
Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy characterized by desmoplastic stroma, immunosuppressive tumor microenvironment (TME), and resistance to standard therapies. Natural killer (NK) ce...
First in human phase 1 study of DT2216, a selective BCL-xL degrader, in patients with relapsed/refractory solid malignancies [0.03%]
DT2216（一种选择性BCL-xL降解剂）治疗复发/难治性实体瘤患者的首次人体Ⅰ期临床研究
Daruka Mahadevan,Minal Barve,Devalingam Mahalingam et al.
Daruka Mahadevan et al.
Background: Small molecule inhibition of BCL-XL with navitoclax resulted in on-target dose-limiting thrombocytopenia. DT2216 was more effective than navitoclax and reduced platelet toxicity in preclinical models by select...
MicroRNA-142 improves IL1RAP CAR-T cell activity in acute myeloid leukemia [0.03%]
microRNA-142可提高CAR-T细胞在急性髓系白血病中的疗效
Kaito Harada,Dandan Zhao,Miso Park et al.
Kaito Harada et al.
Background: Interleukin-1 receptor accessory protein (IL1RAP) is selectively expressed on both bulk blasts and leukemic stem cells (LSCs) in acute myeloid leukemia (AML), while its expression is virtually absent on normal...
Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities [0.03%]
肿瘤中的三级淋巴器官：时空异质性、免疫调控和转化机遇
Shuxuan Deng,Yanjie Chen,Bin Song et al.
Shuxuan Deng et al.
Tertiary lymphoid structures (TLSs) are ectopic lymphoid aggregates that form in or in close proximity to tumors and other chronically inflamed tissues, where they serve as crucial sites for local antigen presentation, lymphocyte priming, a...
Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies [0.03%]
克服抗体药物偶联物的抵抗：从机制见解到前沿策略
Kexun Zhou,Xinrui Liu,Hong Zhu
Kexun Zhou
Antibody-drug conjugates (ADCs) have revolutionized cancer therapy, but therapeutic resistance poses a significant barrier to sustained efficacy. Multiple mechanisms contribute to ADCs resistance, including drug efflux mediated by transport...
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy [0.03%]
靶向PSMA的CAR-巨噬细胞通过驱动代谢重组以增强前列腺癌免疫治疗
Yangli Xu,Duoli Xie,Chunhao Cao et al.
Yangli Xu et al.
Although chimeric antigen receptor (CAR)-T cells have demonstrated remarkable efficacy against hematologic malignancies, their effectiveness in solid tumors is limited by poor tumor infiltration and severe cytokine release syndrome (CRS). C...
The genomic and epigenomic abnormalities of plasma cfDNA as liquid biopsy biomarkers to detect hepatocellular carcinoma: a multicenter cohort study [0.03%]
基于血浆cfDNA的肝细胞癌液体活检生物标志物的基因组及表观基因组异常多中心队列研究
Dezhen Guo,Ao Huang,Jianlong Sun et al.
Dezhen Guo et al.
Circulating tumor DNA (ctDNA) is a promising biomarker for early cancer detection; however, the optimal biomarker approach for early detection of hepatocellular carcinoma (HCC) remains unclear. Furthermore, current next-generation sequencin...
Multicenter Study
Journal of hematology & oncology. 2025 Oct 29;18(1):94. DOI:10.1186/s13045-025-01747-6 2025